Constitutively Active Akt1 Cooperates with KRasG12D to Accelerate In Vivo Pancreatic Tumor Onset and Progression

Neoplasia (United States)

Volumn 17, Issue 2, 2015, Pages 175-182

  Albury, Toya M ^a   Pandey, Veethika ^a   Gitto, Sarah B ^a   Dominguez, Lisette ^a   Spinel, Lina P ^a   Talarchek, Jacqueline ^b   Klein Szanto, Andres J ^b   Testa, Joseph R ^b   Altomare, Deborah A ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; ALPHA SMOOTH MUSCLE ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; KI 67 ANTIGEN; MUCIN; PDX PROTEIN; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; ACTIN; AKT1 PROTEIN, MOUSE; KRAS2 PROTEIN, MOUSE; PROTEIN KINASE B; PROTEIN P21;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENICITY; GENE MUTATION; GENOTYPE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; MYRISTYLATION; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS ISLET CELL CARCINOMA; PANCREATIC STELLATE CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; TUMOR CELL CULTURE; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; FEMALE; GENE EXPRESSION; GENETICS; GENOTYPING TECHNIQUE; MALE; METABOLISM; MUTATION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE;

ACTINS; ANIMALS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION; GENOTYPING TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCINS; MUTATION; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84989352553     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.12.006     Document Type: Article

References (30)

1. [1] Hruban, R.H., Wilentz, R.E., Kern, S.E., Genetic progression in the pancreatic ducts. Am J Pathol 156 (2000), 1821–1825.
2. [2] Hansel, D.E., Kern, S.E., Hruban, R.H., Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 4 (2003), 237–256.
3. [3] Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R., Jacks, T., Tuveson, D.A., Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15 (2001), 3243–3248.
4. [4] Gu, G., Dubauskaite, J., Melton, D.A., Direct evidence for the pancreatic lineage: NGN3 + cells are islet progenitors and are distinct from duct progenitors. Development 129 (2002), 2447–2457.
5. [5] Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 (2003), 437–450.
6. [6] Stanger, B.Z., Stiles, B., Lauwers, G.Y., Bardeesy, N., Mendoza, M., Wang, Y., Greenwood, A., Cheng, K.H., McLaughlin, M., Brown, D., et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8 (2005), 185–195.
7. [7] Elghazi, L., Weiss, A.J., Barker, D.J., Callaghan, J., Staloch, L., Sandgren, E.P., Gannon, M., Adsay, V.N., Bernal-Mizrachi, E., Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology 136 (2009), 1091–1103.
8. [8] Alliouachene, S., Tuttle, R.L., Boumard, S., Lapointe, T., Berissi, S., Germain, S., Jaubert, F., Tosh, D., Birnbaum, M.J., Pende, M., Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation. J Clin Invest 118 (2008), 3629–3638.
9. [9] Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23 (2013), 406–420.
10. [10] Cheng, J.Q., Ruggeri, B., Klein, W.M., Sonoda, G., Altomare, D.A., Watson, D.K., Testa, J.R., Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 93 (1996), 3636–3641.
11. [11] Altomare, D.A., Tanno, S., De Rienzo, A., Klein-Szanto, A., Skele, K.L., Hoffman, J.P., Testa, J.R., Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 87 (2003), 470–476.
12. [12] Foo, W.C., Rashid, A., Wang, H., Katz, M.H., Lee, J.E., Pisters, P.W., Wolff, R.A., Abbruzzese, J.L., Fleming, J.B., Wang, H., Loss of PTEN Expression Is Associated with Recurrence and Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Hum Pathol 44 (2013), 1024–1030.
13. [13] Hill, R., Calvopina, J.H., Kim, C., Wang, Y., Dawson, D.W., Donahue, T.R., Dry, S., Wu, H., PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 70 (2010), 7114–7124.
14. [14] Holland, A.M., Hale, M.A., Kagami, H., Hammer, R.E., MacDonald, R.J., Experimental control of pancreatic development and maintenance. Proc Natl Acad Sci U S A 99 (2002), 12236–12241.
15. [15] Kovacic, S., Soltys, C.L.M., Barr, A.J., Shiojima, I., Walsh, K., Dyck, J.R., Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 278 (2003), 39422–39427.
16. [16] Shiojima, I., Sato, K., Izumiya, Y., Schiekofer, S., Ito, M., Liao, R., Colucci, W.S., Walsh, K., Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115 (2005), 2108–2918.
17. [17] Mukai, Y., Rikitake, Y., Shiojima, I., Wolfrum, S., Satoh, M., Takeshita, K., Hiroi, Y., Salomone, S., Kim, H.H., Benjamin, L.E., et al. Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest 116 (2006), 334–343.
18. [18] Swartz, M.J., Batra, S.K., Varshney, G.C., Hollingsworth, M.A., Yeo, C.J., Cameron, J.L., Wilentz, R.E., Hruban, R.H., Argani, P., MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 117 (2002), 791–796.
19. [19] Rachagani, S., Torres, M.P., Kumar, S., Haridas, D., Baine, M., Macha, M.A., Kaur, S., Ponnusamy, M.P., Dey, P., Seshacharyulu, P., et al. Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. J Hematol Oncol, 5, 2012, 68.
20. [20] Yen, T.W., Aardal, N.P., Bronner, M.P., Thorning, D.R., Savard, C.E., Lee, S.P., Bell, R.H. Jr., Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery 131 (2002), 129–134.
21. [21] Herreros-Villanueva, M., Hijona, E., Cosme, A., Bujanda, L., Mouse models of pancratic cancer. World J Gastroenterol 18 (2012), 1286–1294.
22. [22] Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R.H., Eshleman, J.R., Nowak, M.A., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 (2010), 1114–1117.
23. [23] Garcia-Carracedo, D., Turk, A.T., Fine, S.A., Akhavan, N., Tweel, B.C., Parsons, R., Chabot, J.A., Allendorf, J.D., Genkinger, J.M., Remotti, H.E., et al. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 19 (2013), 6830–6841.
24. [24] Bleeker, F.E., Felicioni, L., Buttitta, F., Lamba, S., Cardone, L., Rodolfo, M., Scarpa, A., Leenstra, S., Frattini, M., Barbareschi, M., et al. AKT1(E17K) in human solid tumours. Oncogene 27 (2008), 5648–5650.
25. [25] Andjelković, M., Alessi, D.R., Meier, R., Fernandez, A., Lamb, N.J., Frech, M., Cron, P., Cohen, P., Lucocq, J.M., Hemmings, B.A., Role of translocation in the activation and function of protein kinase B. J Biol Chem 272 (1997), 31515–31524.
26. [26] Kohn, A.D., Summers, S.A., Birnbaum, M.J., Roth, R.A., Expression of a constitutively active Akt Ser/Thr kinase in 3 T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271 (1996), 31372–31378.
27. [27] Sun, M., Wang, G., Paciga, J.E., Feldman, R.I., Yuan, Z.Q., Ma, X.L., Shelley, S.A., Jove, R., Tsichlis, P.N., Nicosia, S.V., et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159 (2001), 431–437.
28. [28] She, Q.B., Solit, D.B., Ye, Q., O'Reilly, K.E., Lobo, J., Rosen, N., The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8 (2005), 287–297.
29. [29] She, Q.B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K.M., Leander, K.R., DeFeo-Jones, D., Huber, H.E., Rosen, N., Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One, 3, 2008, e3065.
30. [30] Ogawa, K., Sun, C., Horii, A., Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade. Oncol Rep 14 (2005), 1481–1485.